A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

一种治疗自身免疫性白癜风的新型免疫耐受疗法

基本信息

  • 批准号:
    8713488
  • 负责人:
  • 金额:
    $ 22.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), a variant to inducible Heat Shock Protein 70 was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo. Carrying only a single amino acid modification to the protein, this variant HSP70iQ435A (designated "CM") was found to have a curative effect involving long-lasting tolerization of dendritic cells (DCs) and inhibition of T ell influx to the skin. Depigmentation was inhibited by CM DNA vaccination to a remarkable extent in both preventive and therapeutic settings using different spontaneous, T cell receptor transgenic mouse models of vitiligo. Translated to humans, the inflammatory CD11b+CD11c+ subset of DCs held responsible for precipitating and perpetuating vitiligo is found in increased abundance among circulating and skin infiltrating DC. We thus hypothesize that the CM will likewise interfere with progressive depigmentation in human vitiligo. Given the strength and innovation of the basic science investigations and the profound efficacy revealed in multiple animal models of vitiligo, and the clear path forward to clinical proof-of-concept, we now propose an SBIR Phase 1 proposal to advance the CM through demonstration of efficacy in a clinically-relevant large animal model of vitiligo. Specific Aim #1: Establish the efficacy of the M in a large vitiligo model with human-like skin. At RTX the DNA of interest will be subcloned into pUMCV3, a vector suited for human use and expression compared to the original plasmid. 150 mg of CM (>99% purity) in pUMVC3 will then be generated to support large animal efficacy studies as well as for follow-on GLP toxicology and safety pharmacology investigations. Our collaborator, Dr. Le Poole (LUC), will carry out studies in Sinclair pigs (n=6 per group). This model, developing vitiligo as well as melanoma, will serve to test CM DNA application by needle-less jet injection in a model that allows for testing in human-like skin while measuring side-effects on anti-melanoma responses. Efficacy is measured by quantifying changes in lesional area. Local and systemic adverse events will be followed, and immune monitoring performed to translate earlier findings to large animals. This includes analysis of dendritic cell and T cell profiles in blood and skin samples taken from the animals over time. Specific Aim #2: Prepare the CM for IND approval. At RTX, a clinical protocol will be prepared and studies planned to determine the NOAEL, culminating in a pre-IND meeting on preparation for IND approval for a Phase I clinical study. For follow-on GLP toxicology and safety pharmacology investigations, 150 mg of CM (>99% purity) in pUMVC3 will be generated. Clinical investigators will be trained in working with the CM and its application in a pre-clinical setting and to manage any adverse events if necessary. We expect that the CM will induce >50% reduction in vitiligo progression relative to the saline control group and that immune monitoring will determine a > 50% reduction in T cell infiltration to the skin.
描述(由申请人提供):Radikal Therapeutics (RTX)开创了一种新的治疗方法,用于恢复白癜风患者的免疫耐受和阻止进行性色素沉着。在洛约拉大学(LUC),一种诱导热休克蛋白70的变体被开发出来,在预防和治疗自身免疫性白癜风方面具有显著的潜力。这种变体HSP70iQ435A(命名为“CM”)仅携带一个氨基酸修饰蛋白,被发现具有树突状细胞(dc)的持久耐受性和抑制T细胞流入皮肤的疗效。在不同的自发性T细胞受体转基因白癜风小鼠模型中,CM DNA疫苗接种在预防和治疗两种情况下均显著抑制了色素脱失。对于人类来说,在循环和皮肤浸润性DC中,炎症性CD11b+CD11c+亚群的丰度增加,导致白癜风的沉淀和延续。因此,我们假设CM同样会干扰人类白癜风的进行性色素沉着。鉴于基础科学研究的实力和创新,以及在多种白癜风动物模型中显示的深刻疗效,以及临床概念验证的明确路径,我们现在提出SBIR一期提案,通过在临床相关的白癜风大型动物模型中展示疗效来推进CM。具体目标#1:在具有类似人类皮肤的大型白癜风模型中建立M的功效。在RTX,感兴趣的DNA将被亚克隆到pUMCV3中,pUMCV3是一种与原始质粒相比更适合人类使用和表达的载体。然后将生成pUMVC3中的150 mg CM(纯度为99%),以支持大型动物功效研究以及后续的GLP毒理学和安全药理学研究。我们的合作者Le Poole博士(LUC)将在辛克莱猪(每组n=6)中进行研究。这个模型,发展白癜风和黑色素瘤,将用于测试CM DNA的应用,通过无针喷射注射的模型,允许在类似人类的皮肤上进行测试,同时测量抗黑色素瘤反应的副作用。疗效是通过量化病变区域的变化来衡量的。将跟踪局部和全身不良事件,并进行免疫监测,将早期发现转化为大型动物。这包括对长期采集的动物血液和皮肤样本中的树突状细胞和T细胞谱进行分析。具体目标#2:为IND批准准备CM。在RTX,将准备一份临床方案和研究计划,以确定NOAEL,最终在IND前会议上为IND批准I期临床研究做准备。为了进行后续的GLP毒理学和安全药理学研究,将在pUMVC3中生成150 mg CM(纯度为100 - 99%)。临床研究人员将接受培训,在临床前环境中使用CM及其应用,并在必要时管理任何不良事件。我们预计,与生理盐水对照组相比,CM将诱导白癜风进展减少>50%,免疫监测将确定皮肤T细胞浸润减少>50%。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The convergence theory for vitiligo: A reappraisal.
  • DOI:
    10.1111/exd.13677
  • 发表时间:
    2019-06
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Kundu RV;Mhlaba JM;Rangel SM;Le Poole IC
  • 通讯作者:
    Le Poole IC
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW Lurie SALZMAN其他文献

ANDREW Lurie SALZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW Lurie SALZMAN', 18)}}的其他基金

Treatment of congenital heart disease associated pulmonary hypertension
先天性心脏病相关肺动脉高压的治疗
  • 批准号:
    8831801
  • 财政年份:
    2015
  • 资助金额:
    $ 22.5万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9342949
  • 财政年份:
    2012
  • 资助金额:
    $ 22.5万
  • 项目类别:
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic
用硫氧还蛋白模拟物复苏烟雾吸入和烧伤
  • 批准号:
    8338756
  • 财政年份:
    2012
  • 资助金额:
    $ 22.5万
  • 项目类别:
A Redox-active PARP Inhibitor for Lung Transplantation
用于肺移植的氧化还原活性 PARP 抑制剂
  • 批准号:
    8391286
  • 财政年份:
    2012
  • 资助金额:
    $ 22.5万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9140177
  • 财政年份:
    2012
  • 资助金额:
    $ 22.5万
  • 项目类别:
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
双功能氧化还原催化剂
  • 批准号:
    8522327
  • 财政年份:
    2011
  • 资助金额:
    $ 22.5万
  • 项目类别:
PARP inhibition for thoraco-abdominal aneurysm surgery
PARP 抑制在胸腹动脉瘤手术中的应用
  • 批准号:
    6933563
  • 财政年份:
    2005
  • 资助金额:
    $ 22.5万
  • 项目类别:
PARP inhibitory therapy of acute ischemic stroke
PARP抑制治疗急性缺血性脑卒中
  • 批准号:
    6785744
  • 财政年份:
    2004
  • 资助金额:
    $ 22.5万
  • 项目类别:
PARP inhibitor therapy for septic shock
PARP 抑制剂治疗感染性休克
  • 批准号:
    6790412
  • 财政年份:
    2004
  • 资助金额:
    $ 22.5万
  • 项目类别:
Inosine pro-drug: novel therapy for arthritis
肌苷前药:关节炎的新疗法
  • 批准号:
    6867616
  • 财政年份:
    2003
  • 资助金额:
    $ 22.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了